Antiemetic activity of megestrol acetate in patients receiving chemotherapy

Supportive Care in Cancer

Volumn 19, Issue 5, 2011, Pages 667-673

  Zang, Jian ^a   Hou, Min ^a   Gou, Hong Feng ^a   Qiu, Meng ^a   Wang, Jing ^a   Zhou, Xiao Juan ^a   Luo, De Yun ^a   Yang, Yu ^a   Jiang, Ming ^a   Cao, Dan ^a   Bi, Feng ^a   Xu, Feng ^a   Shen, YaLi ^a   Yi, Cheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Emesis; Granisetron; Megestrol acetate; Metoclopramide

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINATE CALCIUM; GRANISETRON; IRINOTECAN; MEGESTROL ACETATE; METOCLOPRAMIDE; OXALIPLATIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG USE; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INCREASED APPETITE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOLID TUMOR; STOMACH CANCER; VAGINA BLEEDING; VEIN THROMBOSIS; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; MALE; MEGESTROL; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; NEOPLASMS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VOMITING;

EID: 79958196161     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0886-x     Document Type: Article

References (22)

1. Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8:187-198
2. Glaus A, Knipping C, Morant R et al (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708-715. doi:10.1007/s00520-004-0662-x (Pubitemid 39362649)
3. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109 (Pubitemid 27020563)
4. Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5:307-313 (Pubitemid 27305081)
5. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer J 100:2261-2268. doi:10.1002/cncr.20230 (Pubitemid 38580348)
6. Gralla RJ (1991) Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res 121:68-85
7. Gralla RJ, Tyson LB, Kris MG et al (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin N Am 71:289-301 (Pubitemid 17052110)
8. KrisMG, Hesketh PJ, SomerfieldMR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932-2947. doi:10.1200/JCO.2006.06.9591
9. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28. doi:10.1093/annonc/mdj078
10. Kaiser R, Sezer O, Papies A et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811 (Pubitemid 34651509)
11. Goodwin JW, Green SJ, Moinpour CM et al (2008) Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 26:1650-1656. doi:10.1200/JCO.2006.10.6179
12. Hedley D, Dalgleish A, Raghavan D et al (1984) Advanced breast cancer: response to high dose oral medroxyprogesterone acetate. Aust N Z J Med 14:251-254 (Pubitemid 15184740)
13. Loprinzi CL, Schaid DJ, Dose AM et al (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152-154 (Pubitemid 23059988)
14. Tomiska M, Tomiskova M, Salajka F et al (2003) Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 50:227-233 (Pubitemid 36830096)
15. Loprinzi CL, Ellison NM, Schaid DJ et al (1990) Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127-1132 (Pubitemid 20213253)
16. Tchekmedyian NS, Hickman M, Siau J et al (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268-1274
17. Rowland KM Jr, Loprinzi CL, Shaw EG et al (1996) Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 14:135-141 (Pubitemid 26020006)
18. Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567-573 (Pubitemid 34072541)
19. Wood L, Palmer M, Hewitt J et al (1998) Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 77:627-631 (Pubitemid 28059471)
20. Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. doi:10.1002/14651858. CD004310.pub2
21. Dev R, Del Fabbro E, Bruera E (2007) Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 110 (6):1173-1177. doi:10.1002/cncr.22924 (Pubitemid 47435585)
22. Levitan N, Dowlati A, Craffey M et al (1998) A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. Lung Cancer 22(3):227-234. doi:10.1016/S0169-5002(98)00087-7 (Pubitemid 29067396)